• Earlier this month, Lam Research announced plans to invest more than US$3.00 billion over five years to expand its global R&D lab network, aiming to lift experiment capacity by over 50% and shorten product development cycles for chipmaking tools used in AI-driven manufacturing.
• This expansion builds on a lab system already running more than one million experiments annually and compressing weeks of work into days, potentially reinforcing Lam’s role as a key process partner for customers pursuing advanced architectures like gate-all-around, 3D NAND and complex packaging.
• Next, we’ll examine how Lam’s multi‑billion‑dollar R&D expansion could reshape its investment narrative built around AI wafer fab equipment demand.

AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Lam Research Investment Narrative Recap

To own Lam Research, you have to believe AI-driven chip complexity keeps lifting demand for its etch and deposition tools, and that Lam can keep executing despite cyclical wafer fab equipment spending and heavy China exposure. The US$3.0 billion R&D lab expansion should reinforce the near term AI equipment catalyst by speeding time to market, but it does not directly reduce the key risks around export controls, customer concentration or memory spending lumpiness.

The recent completion of roughly US$5.95 billion in share repurchases since May 2024 matters here because it amplifies the effect of any R&D-driven product wins on per share earnings. If Lam’s expanded lab network helps it secure a larger share of advanced nodes and packaging tools, that could pair with the smaller share count to support earnings power, even if broader wafer fab equipment spending flattens.

Yet, against this strong AI story, the growing threat of export controls on China is something investors should be aware of because it could...

Lam Research's narrative projects $37.5 billion revenue and $12.4 billion earnings by 2029. This requires 20.0% yearly revenue growth and about a $5.7 billion earnings increase from $6.7 billion today.

Uncover how Lam Research's forecasts yield a $323.38 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already wary, even as they penciled in Lam’s revenue rising toward about US$38.6 billion and earnings to roughly US$14.3 billion by 2029, arguing that export controls and rising Chinese competition could offset gains from AI tools. Their view is far more pessimistic than the consensus and may shift again as the new US$3.0 billion R&D build out filters through future forecasts.

Explore 7 other fair value estimates on Lam Research - why the stock might be worth 46% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Lam Research research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Lam Research research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lam Research's overall financial health at a glance.

Curious About Other Options?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.